Australia markets closed

ME Jan 2025 1.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.55000.0000 (0.00%)
At close: 02:31PM EDT
Full screen
Previous close0.5500
Open0.5500
Bid0.0000
Ask0.8000
Strike1.00
Expiry date2025-01-17
Day's range0.5500 - 0.5500
Contract rangeN/A
Volume10
Open interest1.18k
  • Thomson Reuters StreetEvents

    Q4 2024 23andMe Holding Co. Earnings Call

    Q4 2024 23andMe Holding Co. Earnings Call

  • GlobeNewswire

    23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be available to 23andMe to maxim

  • GlobeNewswire

    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

    Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working direct